PFIZER INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
PFIZER INC (PFE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2011-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2013-02-28
- PFIZER INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2011 was 0.00%, a 100.00% decline from fiscal 2010.
- PFIZER INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2010 was 0.50%, a 150.00% increase from fiscal 2009.
- PFIZER INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2009 was 0.20%, a 90.48% decline from fiscal 2008.
- PFIZER INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2008 was 2.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2011-12-31 | 0.00% 10-K · filed 2013-02-28 |
| 2010-12-31 | 0.50% 10-K · filed 2013-02-28 |
| 2009-12-31 | 0.20% 10-K · filed 2012-02-28 |
| 2008-12-31 | 2.10% 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |